Discover Science: Advances in Radiopharmaceuticals to Diagnose and Treat Diseases
Early disease diagnosis is essential for effective treatment. Dr. Sadeghi’s lab specializes in developing radiolabeled molecules that can help to precisely locate disease within the body which leads to better diagnosis and treatment. Radiopharmaceutical therapy is a form of precision medicine that delivers radiation directly to cancer cells not the entire body — ensuring the right drug is given to the right patient. Join us as we hear from Dr. Saman Sadeghi, Associate Professor in the Department of Chemistry & Chemical Biology, and Principal Investigator at McMaster Radiochemistry and Radiopharmaceuticals, as he discusses the molecular imaging and radiopharmaceuticals program at McMaster and the significant impact of this research. Q & A will follow.

The Science Series: ADCs and radiopharmaceuticals

What is Nuclear Medicine and Molecular Imaging?

Behind the Breakthroughs 2026

New MRI methods and preclinical models to assess the brain tumor microenvironment | Webinar

Journal Club | Photoreceptor Cell Therapy to Treat Advanced Retinal Degeneration

Physics Hours ft. Dr Claudiu Gradinaru

The Future of Radiopharmaceuticals | Christopher P. Leamon | CANM'23

What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service

#3 2025 08 23 Cancer Center Lynch Syndrome Symposium Preventing Cancers in Lynch Syndrome

NestJS Full Course in 2026 | How Senior Engineers Build Backends with AI

Engineering Functionally Improved CAR T cells with a Multi-Cytokine Backpack Platform | REBEL System

LRR Microbiology for FMGE 2026 By Dr. Preeti Sharma

Brian Cox: The quantum roots of reality | Full Interview

Billionaire's WARNING: I'm SELLING. The Crash Is Already Here!

Journal Club | Gene-Agnostic Gene Therapy to Preserve Vision

The World's Most Important Machine

Vision as We Age: Understanding Common Eye Conditions

Blood Stem Cells, Aging, and Inflammation

DIRECTO | Powell se somete al Congreso: ¿dará más pistas de la bajada de tipos?

